Format

Send to

Choose Destination
Int J Mol Sci. 2017 Apr 14;18(4). pii: E837. doi: 10.3390/ijms18040837.

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Author information

1
Instituto Português de Oncologia de Lisboa (IPOL), 1200-795 Lisbon, Portugal. amalmeida@ipolisboa.min-saude.pt.
2
Institut Paoli Calmettes, Marseille, France and Yale New Haven Hospital, New Haven, CT 06512, USA. thomas.prebet@yale.edu.
3
Hopital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Diderot University, 75010 Paris, France. itzykson@gmail.com.
4
Hospital Universitario de Leon, 24071 Leon, Spain. mail@fernandoramosmd.es.
5
University Hospital of Halle, 06120 Halle, Germany. alah@medizin.uni-leipzig.de.
6
Rush University Medical Center, Chicago, IN 60612, USA. Jamile_Shammo@rush.edu.
7
Hospital Sao Joao, 4200-319 Porto, Portugal. rjsmpinto@gmail.com.
8
University Tor Vergata, 00173 Rome, Italy. luca.maurillo@uniroma2.it.
9
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA. FENSTEJ@ccf.org.
10
RCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture (Pz), Italy. p.musto@tin.it.
11
Department of Hematology VU University Medical Center, 1081 HV Amsterdam, The Netherlands. a.vandeloosdrecht@vumc.nl.
12
Centro Hospitalar Lisboa Norte Hospital Santa Maria, 1649-035 Lisbon, Portugal. mjoaocosta@gmail.com.
13
Instituto Português de Oncologia de Lisboa (IPOL), 1200-795 Lisbon, Portugal. sesteves@ipolisboa.min-saude.pt.
14
Department of Internal Medicine IV, Hospital Wels-Grieskirchen, 4600 Wels, Austria. sonja.burgstaller@klinikum-wegr.at.
15
Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, 6020 Innsbruck, Austria. reinhard.stauder@i-med.ac.at.
16
1st Department of Internal Medicine, Center for Oncology and Hematology, Wilhelminenspital, 1160 Vienna, Austria. eva-maria.autzinger@wienkav.at.
17
Internal Medicine, Hospital Feldkirch,6800 Feldkirch, Austria. alois.lang@lkhf.at.
18
Department of Internal Medicine, Hospital Fürstenfeld, 8280 Fürstenfeld, Austria. peter.krippl@lkh-fuerstenfeld.at.
19
Department for Internal Medicine, Klinikum Klagenfurt am Wörthersee, 9020 Pörtschach am Wörthersee, Austria. dietmar.geissler@kabeg.at.
20
Hospital Universitario Virgen del Rocio, 41013 Sevilla, Spain. jfalantes@gmail.com.
21
Hospital del Mar, 08003 Barcelona, Spain. MPedro@parcdesalutmar.cat.
22
Hospital Son Llatzer, 07198 Palma de Mallorca, Spain. jbargay@hsll.es.
23
Hospital Universitario, 15006 A Coruña, Spain. gdebari@canalejo.org.
24
Hospital de la Santa Creu i Sant Pau, 08026 Barcelona, Spain. AGarridoD@santpau.cat.
25
Hospital Universitario de la Ribera, 46600 Alzira, Spain. sbonanad@gmail.com.
26
Hospital Universitario de Salamanca, 37007 Salamanca, Spain. mdiezcampelo@usal.es.
27
Centre Hospitalier Universitaire, 49100 Angers, France. Sylvain.Thepot@chu-angers.fr.
28
Hopital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Diderot University, 75010 Paris, France. lionel.ades@sls.aphp.fr.
29
Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, 1090 Vienna, Austria. wolfgang.r.sperr@meduniwien.ac.at.
30
Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, 1090 Vienna, Austria. peter.valent@meduniwien.ac.at.
31
Hopital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Diderot University, 75010 Paris, France. pierre.fenaux@sls.aphp.fr.
32
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA. SEKEREM@ccf.org.
33
3rd Med. Department, Paracelsus Medical University, 5020 Salzburg, Austria. r.greil@salk.at.
34
Salzburg Cancer Research Institute, 5020 Salzburg, Austria. r.greil@salk.at.
35
Cancer Cluster Salzburg, 5020 Salzburg, Austria. r.greil@salk.at.
36
Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), 5020 Salzburg, Austria. r.greil@salk.at.
37
3rd Med. Department, Paracelsus Medical University, 5020 Salzburg, Austria. l.pleyer@salk.at.
38
Salzburg Cancer Research Institute, 5020 Salzburg, Austria. l.pleyer@salk.at.
39
Cancer Cluster Salzburg, 5020 Salzburg, Austria. l.pleyer@salk.at.
40
Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), 5020 Salzburg, Austria. l.pleyer@salk.at.

Abstract

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.

KEYWORDS:

acute erythroleukemia; azacitidine; decitabine

PMID:
28420120
PMCID:
PMC5412421
DOI:
10.3390/ijms18040837
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center